PONY(SZ:300887)2021-10-25 16:00Revenue and Profitability - The company's revenue for Q3 2021 reached ¥603,014,509.38, representing a year-on-year increase of 57.48%[3] - Net profit attributable to shareholders was ¥66,741,577.20, up 83.22% compared to the same period last year[3] - The net profit excluding non-recurring items was ¥62,281,513.52, reflecting a significant increase of 133.86% year-on-year[3] - The total operating revenue for the period reached CNY 1,341,708,482.18, a significant increase of 45.5% compared to CNY 922,716,199.43 in the previous period[27] - Net profit for the period was CNY 93,106,778.91, representing a 78.7% increase from CNY 52,104,378.16 in the same period last year[28] - Basic and diluted earnings per share were both CNY 0.6806, compared to CNY 0.4987 in the previous period, reflecting a growth of 36.5%[29] Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥2,495,235,265.40, an increase of 18.08% from the end of the previous year[3] - The company's total liabilities reached CNY 609,859,916.77, up from CNY 292,559,689.56, indicating a growth of 108.5%[28] - The company's total current liabilities rose to CNY 481,325,250.73 from CNY 245,888,348.18, an increase of around 96%[25] - The total liabilities rose to 399,946,492.45 CNY from 292,559,689.56 CNY, with a notable increase in non-current liabilities attributed to lease liabilities[35] Cash Flow - The company’s cash flow from operating activities showed a negative net amount of ¥107,072,623.70, a significant decline of 8,701.94%[3] - Operating cash inflow totaled ¥1,067,183,500.62, an increase of 16.76% compared to ¥913,973,974.61 in the same period last year[10] - Operating cash outflow increased by 28.31% to ¥1,174,256,124.32 from ¥915,190,441.40 year-on-year[10] - The net cash flow from operating activities was -107,072,623.70 CNY, compared to -1,216,466.79 CNY in the previous year, indicating a significant increase in cash outflow[32] - The net cash flow from financing activities was -3,124,798.93 CNY, a decrease from 798,216,317.15 CNY in the previous year, reflecting a substantial reduction in financing inflows[32] Investments and Expenses - Research and development expenses increased by 51.83% to ¥103,034,597.59, indicating a commitment to innovation[9] - Investment cash inflow surged by 245.12% to ¥207,749,160.90, mainly from the redemption of financial products[10] - Investment cash outflow rose by 115.43% to ¥455,188,437.24, driven by capacity expansion and equipment purchases[10] - The total operating costs amounted to CNY 1,240,604,747.60, up 40.9% from CNY 880,485,699.42 in the prior period[28] Goodwill and Intangible Assets - The company acquired several medical testing laboratories, resulting in goodwill increasing by 7,838.53% to ¥27,347,012.74[7] - The company’s goodwill increased significantly to CNY 27,347,012.74 from CNY 344,484.50, indicating a substantial rise[25] - The company’s intangible assets rose to CNY 87,831,929.07 from CNY 73,559,814.11, an increase of about 19%[25] Operational Developments - The company completed the registration of the first grant of restricted stock under the 2021 incentive plan, with 357 participants subscribing to a total of 220,570 shares[20] - The company’s subsidiary, Suzhou Puni Medical Laboratory, was designated as a designated institution for COVID-19 testing in Suzhou[21] - The company’s subsidiary, Tianjin Puni Medical Laboratory, has been confirmed to have the capability to conduct COVID-19 nucleic acid testing[21] Financial Reporting and Audit - The company has not undergone an audit for the third quarter report, which may affect the reliability of the financial data presented[37] - The company is adjusting its financial statements in accordance with new leasing standards, which may affect future financial reporting and analysis[33]